ISDA

Deposition Date 2015-09-22

Release Date 2015-11-11

Last Version Date 2024-10-16

Entry Detail

PDB ID:

5DWR

Keywords:

Transferase/Transferase Inhibitor

Title:

Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1,2 and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.20

R-Value Work:

0.17

R-Value Observed:

0.17

Space Group:

P 65

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Serine/threonine-protein kinase pim-1
Gene (Uniprot):PIM1
Chain IDs:A
Chain Length:328
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P11309 Pfam ID:PF00069 EC:2.7.11.1

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
SEP	A	SER	modified residue

Ligand Molecules

5H7

Primary Citation

Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies.

Burger, M.T, Nishiguchi, G, Han, W, Lan, J, Simmons, R, Atallah, G, Ding, Y, Tamez, V, Zhang, Y, Mathur, M, Muller, K, Bellamacina, C, Lindvall, M.K, Zang, R, Huh, K, Feucht, P, Zavorotinskaya, T, Dai, Y, Basham, S, Chan, J, Ginn, E, Aycinena, A, Holash, J, Castillo, J, Langowski, J.L, Wang, Y, Chen, M.Y, Lambert, A, Fritsch, C, Kauffmann, A, Pfister, E, Vanasse, K.G, Garcia, P.D.Show

J.Med.Chem. 58 8373 8386 (2015)

PMID: 26505898 DOI: 10.1021/acs.jmedchem.5b01275

Abstact

Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound 3, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound 8 entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures